



LKT Laboratories, Inc.

## Bezafibrate

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

### Product Information

**Product ID** B1898

**CAS No.** 41859-67-0

**Chemical Name** 2-[4-[2-[(4-Chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid

**Synonym** Befizal, Bezatol, Cedur, Difaterol

**Formula** C<sub>19</sub>H<sub>20</sub>ClNO<sub>4</sub>

**Formula Wt.** 361.82

**Melting Point** 186 °C


**Purity** ≥98%

**Solubility** Soluble in DMSO  
(50mg/mL).

**Store Temp** Ambient

**Ship Temp** Ambient

**Description** Bezafibrate is a PPAR $\alpha$  agonist that is clinically used to lower LDL and triglyceride levels and to increase HDL levels. Bezafibrate exhibits anti-hyperlipidemic, cardioprotective, anti-diabetic, anti-osteoporotic, and anticancer chemotherapeutic activities. When administered clinically, bezafibrate decreases risk of myocardial infarction and cardiac mortality; it also decreases the incidence and delays the onset of type 2 diabetes. Bezafibrate promotes bone formation by activating proliferation and differentiation of osteoblasts in vitro in an AMPK- and PPAR $\beta$ -dependent manner. In animal models of non-small cell lung cancer (NSCLC), bezafibrate decreases angiogenesis and tumor growth through downregulation of Cyp2c expression or activity.



**Bulk quantities available upon request**

Product ID	Size
B1898	1 g
B1898	5 g
B1898	25 g

**References** Skrypyk N, Chen X, Hu W, et al. PPAR $\alpha$  activation can help prevent and treat non-small cell lung cancer. *Cancer Res.* 2014 Jan 15;74(2):621-31. PMID: 24302581.

Zhong X, Xiu LL, Wei GH, et al. Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation. *Acta Pharmacol Sin.* 2011 May;32(5):591-600. PMID: 21499286.

Tenenbaum A, Motro M, Fisman EZ, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. *Arch Intern Med.* 2005 May 23;165(10):1154-60. PMID: 15911729.

Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. *Circulation.* 2004 May 11;109(18):2197-202. PMID: 15123532.

Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. *Circulation.* 2000 Jul 4;102(1):21-7. PMID: 10880410.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.